PMID- 25176938
OWN - NLM
STAT- MEDLINE
DCOM- 20150723
LR  - 20171116
IS  - 1942-3268 (Electronic)
IS  - 1942-3268 (Linking)
VI  - 7
IP  - 6
DP  - 2014 Dec
TI  - Plasma concentrations of afamin are associated with the prevalence and 
      development of metabolic syndrome.
PG  - 822-9
LID - 10.1161/CIRCGENETICS.113.000654 [doi]
AB  - BACKGROUND: Afamin is a human plasma vitamin E-binding glycoprotein primarily 
      expressed in the liver and secreted into the bloodstream. Because little is known 
      about (patho)-physiological functions of afamin, we decided to identify 
      phenotypes associated with afamin by investigating transgenic mice overexpressing 
      the human afamin gene and performing large-scale human epidemiological studies. 
      METHODS AND RESULTS: Transgenic mice overexpressing afamin revealed increased 
      body weight and serum concentrations of lipids and glucose. We applied a 
      random-effects meta-analysis using age- and sex-adjusted baseline and follow-up 
      investigations in the population-based Bruneck (n=826), Salzburg Atherosclerosis 
      Prevention Program in Subjects at High Individual Risk (SAPHIR; n=1499), and 
      KOoperative Gesundheitsforschung in der Region Augsburg (KORA) F4 studies 
      (n=3060). Mean afamin concentrations were 62.5+/-15.3, 66.2+/-14.3, and 70.6+/-17.2 
      mg/L in Bruneck, SAPHIR, and KORA F4, respectively. Per 10 mg/L increment in 
      afamin measured at baseline, the number of metabolic syndrome components 
      increased by 19% (incidence rate ratio=1.19; 95% confidence interval [CI], 
      1.16-1.21; P=5.62x10(-64)). With the same afamin increment used at baseline, we 
      observed an 8% gain in metabolic syndrome components between baseline and 
      follow-up (incidence rate ratio=1.08; 95% CI, 1.06-1.10; P=8.87x10(-16)). Afamin 
      concentrations at baseline were highly significantly related to all individual 
      metabolic syndrome components at baseline and at follow-up. This observation was 
      most pronounced for elevated waist circumference (odds ratio, 1.79; 95% CI, 
      1.54-2.09; P=4.15x10(-14) at baseline and odds ratio, 1.46; 95% CI, 1.31-1.63; 
      P=2.84x10(-11) for change during follow-up) and for elevated fasting glucose 
      concentrations (odds ratio, 1.46; 95% CI, 1.40-1.52; P=1.87x10(-69) and odds 
      ratio, 1.46; 95% CI, 1.24-1.71; P=5.13x10(-6), respectively). CONCLUSIONS: This 
      study in transgenic mice and >5000 participants in epidemiological studies shows 
      that afamin is strongly associated with the prevalence and development of 
      metabolic syndrome and all its components.
CI  - (c) 2014 American Heart Association, Inc.
FAU - Kronenberg, Florian
AU  - Kronenberg F
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Kollerits, Barbara
AU  - Kollerits B
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Kiechl, Stefan
AU  - Kiechl S
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Lamina, Claudia
AU  - Lamina C
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Kedenko, Lyudmyla
AU  - Kedenko L
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Meisinger, Christa
AU  - Meisinger C
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Willeit, Johann
AU  - Willeit J
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Huth, Cornelia
AU  - Huth C
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Wietzorrek, Georg
AU  - Wietzorrek G
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Altmann, Maria E
AU  - Altmann ME
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Thorand, Barbara
AU  - Thorand B
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Melmer, Andreas
AU  - Melmer A
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Dahnhardt, Doreen
AU  - Dahnhardt D
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Santer, Peter
AU  - Santer P
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Rathmann, Wolfgang
AU  - Rathmann W
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Paulweber, Bernhard
AU  - Paulweber B
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Koenig, Wolfgang
AU  - Koenig W
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Peters, Annette
AU  - Peters A
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Adham, Ibrahim M
AU  - Adham IM
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.).
FAU - Dieplinger, Hans
AU  - Dieplinger H
AD  - From the Division of Genetic Epidemiology (F.K., B.K., C.L., D.D., H.D.), 
      Division of Molecular and Cellular Pharmacology, Department of Medical Genetics, 
      Molecular, and Clinical Pharmacology (G.W.), Department of Neurology (S.K., 
      J.W.), Department of Internal Medicine I (A.M.), Innsbruck Medical University, 
      Innsbruck, Austria; First Department of Internal Medicine, Paracelsus Private 
      Medical University, Salzburg, Austria (L.K., B.P.); Institute of Epidemiology II, 
      Helmholtz Zentrum Munchen-German Research Center for Environmental Health, 
      Oberschleissheim, Germany (C.M., C.H., B.T., A.P.); German Center for Diabetes 
      Research (DZD), Neuherberg, Germany (C.M., C.H., B.T., A.P.); Institute of Human 
      Genetics, University of Gottingen, Gottingen, Germany (M.E.A. I.M.A.); Department 
      of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy (P.S.); Institute of 
      Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes 
      Research at Heinrich Heine, University Dusseldorf, Dusseldorf, Germany (W.R.); 
      Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, 
      Ulm, Germany (W.K.); and Vitateq Biotechnology GmbH, Innsbruck, Austria (H.D.). 
      hans.dieplinger@i-med.ac.at.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140831
PL  - United States
TA  - Circ Cardiovasc Genet
JT  - Circulation. Cardiovascular genetics
JID - 101489144
RN  - 0 (AFM protein, human)
RN  - 0 (Blood Glucose)
RN  - 0 (Carrier Proteins)
RN  - 0 (Glycoproteins)
RN  - 0 (Serum Albumin)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Blood Glucose/analysis
MH  - Body Weight
MH  - Carrier Proteins/*blood
MH  - Databases, Factual
MH  - Female
MH  - Follow-Up Studies
MH  - Glycoproteins/*blood
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Metabolic Syndrome/*epidemiology/pathology
MH  - Mice
MH  - Mice, Transgenic
MH  - Middle Aged
MH  - Odds Ratio
MH  - Phenotype
MH  - Prevalence
MH  - Serum Albumin
MH  - Serum Albumin, Human
OTO - NOTNLM
OT  - afamin protein, human
OT  - epidemiology
OT  - glucose
OT  - lipoproteins
OT  - metabolic syndrome X
OT  - metabolism
OT  - obesity
EDAT- 2014/09/02 06:00
MHDA- 2015/07/24 06:00
CRDT- 2014/09/02 06:00
PHST- 2014/09/02 06:00 [entrez]
PHST- 2014/09/02 06:00 [pubmed]
PHST- 2015/07/24 06:00 [medline]
AID - CIRCGENETICS.113.000654 [pii]
AID - 10.1161/CIRCGENETICS.113.000654 [doi]
PST - ppublish
SO  - Circ Cardiovasc Genet. 2014 Dec;7(6):822-9. doi: 10.1161/CIRCGENETICS.113.000654. 
      Epub 2014 Aug 31.